Peginterferon alfa-2a Articles
Roche's Pegasys gets EU backing for chronic hepatitis C in children aged five years and older
18 March 2013
News briefs: Rituximab biosimilar; Watson to change name; Baxter Brazil plans; India revokes Pegasys patent
5 November 2012
Uptake of Peg-IFN agents for HCV in China and South Korea hindered by relatively high cost and their partial reimbursement status
21 October 2012
Licensing deals: Debiopharm/Novartis; Teva/Active Biotech; Qiagen on biomarker; Merck & Co/AnaptysBio; and Novavax/ROVI accord dropped
9 February 2010
Roche 2009 figures miss targets, hit by Genentech buy costs and slowing sales of some cancer drugs
3 February 2010
Larger proportion of hepatitis C non-responder patients in USA will get telaprevir therapy than boceprevir, study shows
20 January 2010
Russia's hepatitis C virus drug market set to grow 9% annually, reaching $327 million by 2013
3 December 2009
Biosimilars of TNF-alpha inhibitors stand to erode over $9 billion in brand sales in USA and Europe by 2018
4 November 2009
Roche nine-month 2009 sales boosted by strong Tamiflu showing
15 October 2009
Stock Commentary - New York week to April 27, 2009
30 April 2009
Romark's nitazoxanide boosts SVR of SOC
30 March 2009
Advantages of telaprevir- and boceprevir-based regimens
23 March 2009
HGS/Novartis drug non- inferior to Pegasys
16 March 2009
Japan stock market week to Feb 23, 2009
2 March 2009
Roche's profit falls 5% on lower Tamiflu sales
9 February 2009
Roche agrees hep C trial design with FDA
19 January 2009
Pegasys/Copegus effective in non-responders
10 November 2008
Expanded European indication for Roche's Pegasys/Copegus
8 November 2008
China hep C market to grow to $150M in 2012
15 September 2008
China's hep B market $800M by 2012
8 September 2008
Roche to lift stake in Chugai to 59.9%
2 June 2008
Promising Ph IIa data on Roche's R1626
5 May 2008
Similar SVRs for S-P and Roche HCV combos
5 May 2008
Roche invests $389M in Germany, Switzerland
28 January 2008
GSK initiates Ph III hep C Promacta studies
21 November 2007
Roche drug combo helps Pegintron-resistant patients
21 November 2007
Strong HCV clearance data for R1626 regimen
21 November 2007
HGS' Albuferon sees strong Ph IIb data
12 November 2007
Roche initiates landmark HCV drug therapy trial
24 September 2007
Roche initiates PROGRESS trial
19 March 2007
EC clears short-course Pegasys/Copegus
12 March 2007
Copegus/Pegasys gets MHLW OK for Hep C
5 February 2007
SVR for early responders on Pegasys/Copegus
6 November 2006
Pfizer's celecoxib to become Japan's first COX-2 inhibitor
30 October 2006
Roche initiates Ph II trial of novel HCV drug
23 October 2006
UK OKs combination hepatitis C treatments
4 September 2006
UK's NICE guidance on hepatitis C treatment OKs two drugs
28 August 2006
Roche's Copegus/Pegasys "cost effective," study
29 May 2006
Roche's Pegasys "better at 24, not 16 weeks"
8 May 2006
Strong Ph I data for Roche's novel HCV drug
8 May 2006
Copegus 400mg OKed in Holland, MRP begun
1 May 2006
UK's NICE recommends Roche's PegaSys
27 February 2006
Teva, Three RIvers and Par get final OK for generic ribavarin
12 December 2005
Roche and Chugai hep C drug under priority review
19 September 2005
Trial shows Pegasys' superior efficacy in HBV
11 July 2005
Roche's anti-HCV combo performs well in Japan
27 June 2005
Stock Commentary - Europe
30 May 2005
Roche's PEGASYS gets US OK in hep B
23 May 2005
Clarification:
28 April 2005
PegIntron/Rebetol in HCV: positive data
25 April 2005
Pegasys treatment of choice says manufacturer
14 March 2005
EC approves Roche's Pegasys for hepatitis B
7 March 2005
EC clears Pegasys for hep C + HIV co-infection
7 February 2005
CHMP recommends Roche's Pegasys as hep B therapy
31 January 2005
Roche's Pegasys obtains Swiss approval for chronic hep B
10 January 2005
Roche's Pegasys on track for new use in EU
10 January 2005
Roche's Pegasys gets expanded label in EU
22 November 2004
Japan's Chugai posts nine-month results in line with forecasts
8 November 2004
Priority review for Roche's Pegasys sBLA
11 October 2004
Stock Commentary - Europe
27 September 2004
Roche files for new use of Pegasys
13 September 2004
Roche's net income doubles for 1st-half
26 July 2004
Roche's Pegasys filed for hepatitis B
26 July 2004
Tokyo pharma stocks - week July 19
26 July 2004
Roche 1st-qtr beats expectations
26 April 2004
Pegasys still driving Roche's growth
29 March 2004
Genotype can determine duration of Hep C therapy
8 March 2004
Promising new data for SciClone's Zadaxin
1 March 2004
Roche beats forecasts with sales up 19%
9 February 2004
Tokyo pharma stocks - week to Dec 15
22 December 2003
Roche signs Japanese deal with Chugai
22 December 2003
Tokyo pharma stocks - week to Dec 8
15 December 2003
Tokyo pharma stocks - week to Sept 29
3 November 2003
Roche's Pegasys gains Japanese approval
27 October 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
S-P to compare hep C therapies
6 October 2003
Roche posts sharp fall in 1st-half profit
28 July 2003
EC changes label for Roche's Pegasys
28 July 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
